pimobendan has been researched along with dipyridamole in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Belch, JJ; Forbes, CD; Lowe, GD; Saniabadi, AR | 1 |
| Eisert, WG; Eldor, A; Fuks, Z; Muller, TH; Vlodavsky, I | 1 |
3 other study(ies) available for pimobendan and dipyridamole
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Platelet aggregation inhibitory effects of the new positive inotropic agents pimobendan and UD CG 212 in whole blood.
Topics: Adult; Blood Platelets; Cardiotonic Agents; Dipyridamole; Drug Synergism; Female; Humans; Male; Microscopy, Electron; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyridazines | 1989 |
Different effects of aspirin, dipyridamole and UD-CG 115 on platelet activation in a model of vascular injury: studies with extracellular matrix covered with endothelial cells.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Blood Platelets; Cattle; Cells, Cultured; Dipyridamole; Endothelium; Epoprostenol; Extracellular Matrix; Humans; Models, Biological; Platelet Aggregation; Pyridazines; Thromboxanes | 1986 |